Biogen Working With Capsigen to Develop Gene Therapies for CNS, Neuromuscular Disorders
05:57 AM EDT, 05/11/2021 (MT Newswires) -- Biogen (BIIB) said Monday it is pursuing a research collaboration with Capsigen to develop novel adeno-associated virus capsids that have the potential to deliver gene therapies for various disorders in the central nervous system and neuromuscular disorders.
Under the collaboration, Biogen will obtain an exclusive license under Capsigen's proprietary technology for an undisclosed number of central nervous system and neuromuscular disease targets. Meanwhile, Capsigen will get a $15 million upfront payment as well as up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial payments along with royalties on future net sales of the products.
Capsigen will deploy its proprietary TRADE platform to create and identify novel adeno-associated virus capsids tailored to meet disease-specific transduction profiles while Biogen will leverage its discovery, development, manufacturing and commercialization capabilities.
Price: 273.21, Change: -2.40, Percent Change: -0.87